22P Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A real-world study from the ARON-2EV project
Year: 2026
Type: article
Study design: Observational Study
Abstract: Enfortumab vedotin (EV) has been approved for the treatment of metastatic urothelial carcinoma (mUC), either as monotherapy or in combination with immune checkpoint inhibitors, following results of recent practice-changing clinical trials. However, limited data exist regarding patients with bone metastases, leaving a critical gap in knowledge regarding the efficacy of EV in this subgroup. The study aimed to evaluate the impact of bone metastases in patients with mUC treated with EV using data the ARON global real-world retrospective database.
Source: ESMO Open
Institutions: Istituto Tumori Bari, University of Kentucky, Carol Davila University of Medicine and Pharmacy, Ochsner Health System, Ochsner Medical Center, University Hospital Hradec Králové, Kindai University, Sapienza University of Rome, Samsung Medical Center, Sungkyunkwan University, Masaryk University, The Maria Sklodowska-Curie National Research Institute of Oncology, Hospital Sírio-Libanês, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Hospital Universitario Ramón y Cajal, Ospedale di Macerata
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7147377541
FWCI:
Cites:
Cited by:
Related to: